Enterome to Present Data on OncoMimics™ Approach to Cancer Immunotherapy at EACR 2024

Paris, France – June 11th, 2024

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, will present data on its innovative OncoMimics™ approach to cancer therapy at the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), taking place June 10-13 in Rotterdam, Netherlands. The presentation describes Enterome's OncoMimics™ peptide-based immunotherapy, designed to harness the patient's immune system to target and eliminate cancer cells.

Dr. Alice Talpin, lead researcher, commented: "The OncoMimics™ approach offers a promising strategy to enhance cancer immunity by overcoming the limitations of current vaccines. Our preclinical and clinical data underscore the ability of OncoMimics™ peptides to elicit strong, durable immune responses, which could significantly improve patient outcomes."

Peptide-based immunotherapy offers significant potential against cancer by leveraging the body's immune system to eliminate cancer cells, targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Enterome innovative OncoMimics™ therapies are based on the concept of molecular mimicry and cross-reactivity between commensal-derived synthetic peptides and tumor-associated antigens-derived peptides (TAAps) to evoke a $CD8^+$ T cell response against tumors.

Based on this approach, Enterome has developed a pipeline of drug candidates for the treatment of cancer, including EO2463, which is demonstrating a favorable safety profile with encouraging early signs of efficacy in a Phase 2 clinical trial (EONHL1-20/SIDNEY) for indolent non-Hodgkin lymphomas, and EO2401, which has successfully completed a Phase 2 clinical trial (EOGBM1-18/ROSALIE) in patients with recurrent glioblastoma.

Highlights from the EACR 2024 poster presentation, entitled *Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens*:

In humanized HLA-A2 murine models, OncoMimics™ peptides (OMPs) trigger the expansion of cross-reactive OMP-/TAAp- specific $CD8^+$ T cells with specific cytotoxic activity against tumor cells. Experiments conducted on HLA-$A2^+$ healthy human peripheral blood mononuclear cells revealed a high prevalence of cross-reactive OMP-/TAAp-specific $CD8^+$ T cells when stimulated in vitro. In addition, those cross-reactive $CD8^+$ T cells exhibit cytolytic activity against target cells presenting homologous TAAs.

Abstract #1155 is published in an online supplement to *Molecular Oncology* (Volume 18, Issue S1, DOI: 10.1002/1878-0261.13683) and the Poster will be available on Enterome's website following the session.

Poster #1155 Presentation details

Title: *Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens*
Presenting Author: Alice Talpin, PhD, Enterome researcher
Poster Session: Immunotherapy (odd Abstract Numbers)
Poster Board: P-285
Session Date and Time: June 12, 18:40 to 20:15 CET (poster displayed from 11:00 CET)

Contacts

ENTEROME	MEDIA RELATIONS
Guillaume Bayre **Head of External Communications** Tel: +33 (0)1 76 21 58 15 communication@enterome.com	**LifeSci Advisors LLC** Ashley R. Robinson (US) +1 617 430 7577 **arr@lifesciadvisors.com** Sandya von der Weid (Europe) +41 78 680 05 38 **svonderweid@lifesciadvisors.com**

About Enterome

Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome's pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.

Enterome's first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect, or actions of specific antigens, hormones, or cytokines.

The company is currently developing a pipeline of drug candidates consisting of:

- **OncoMimics™** peptide-based immunotherapies for the treatment of cancer, including EO2463, and EO2401. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphomas, demonstrating a benign safety profile with encouraging early signs of efficacy. EO2401 has successfully completed a Phase 2 clinical trial in patients with glioblastoma, and Enterome is currently seeking a pharmaceutical partner to further develop a pivotal trial.
- **EndoMimics™** peptides, a pipeline of next-generation bioactive therapeutic proteins acting like human hormones or cytokines, being developed in collaboration with Nestlé

Health Science for food allergies and inflammatory bowel disease (IBD). The lead candidate, EB1010, is preparing to enter clinical development.

Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships.

For more information, please visit the company's website at: **www.enterome.com**